(Q28237583)

2

0 references

David Kardatzke

6

0 references

Lisa Lancaster

8

0 references

Javier Szwarcberg

10

0 references

Dominique Valeyre

11

0 references

Paul W. Noble

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

Williamson Z. Bradford

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

Marilyn K. Glassberg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

Talmadge E. King

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

Steven A. Sahn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

Roland M. du Bois

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

CAPACITY Study Group

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

2 December 2024

language of work or name

English

0 references

publication date

21 May 2011

0 references

13 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21571362

full work available at URL

2 December 2024

https://api.elsevier.com/content/article/PII:S0140673611604054?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)60405-4

https://api.elsevier.com/content/article/PII:S0140673611604054?httpAccept=text/plain

2 December 2024

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)60405-4

2 December 2024

0 references

377

0 references

issue

9779

0 references

page(s)

1760-9

0 references

cites work

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Determinants of survival in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Lung Fibrosis is Ameliorated by Pirfenidone Fed in Diet After the Second Dose In A Three-Dose Bleomycin-Hamster Model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Pirfenidone in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Small changes in six-minute walk distance are important in diffuse parenchymal lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Non-steroid agents for idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

High-dose acetylcysteine in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960405-4

7 January 2021

Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis

5

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)60405-4

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters

2 December 2024

10

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(11)60405-4

2 December 2024

Identifiers

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017